The role of myeloperoxidase (MPO) for prognostic evaluation in sensitive cardiac troponin I negative chest pain patients in the emergency department

Abstract

Background:

The diagnostic work-up of patients with acute chest pain in the emergency department (ED) is a challenging task. Serial troponin testing is required to rule-out acute myocardial infarction.

Objective:

To evaluate the value of myeloperoxidase (MPO) testing in sensitive cardiac troponin I (cTnI) negative patients with suspected acute coronary syndromes (ACS) in the routine setting of an ED.

Methods:

MPO was assessed in 432 consecutive patients presenting to the ED with ACS. In 266 patients, serial blood samples were available. After 6 weeks, major adverse cardiac events (MACE) were assessed. MPO and cTnI were measured in all available samples. For cTnI, a sensitive assay was used. Cut-off values were derived from an independent sample of 300 healthy volunteers.

Results:

Incidence of MACE in our population was 13%. MPO levels revealed sensitivity (Sens) of 82.1% and specificity (Spec) of 37.2% for MACE compared with 60.7% Sens and 61.4% Spec for sensitive cTnI. In serial sensitive cTnI negative patients (n=218), MACE incidence was 6.4%. MPO continued to demonstrate significant discriminatory power for the prognosis of MACE. Multivariate analyses confirmed these findings.

Conclusion:

MPO has an independent prognostic value overall and most notably in patients tested negative with a higher sensitive cardiac troponin I assay. MPO could be a promising biomarker for the initial evaluation of patients in chest pain units and is worth further investigation.

Keywords

Acute coronary syndrome MACE (major adverse cardiac events)pre-analytical effects

Get full access to this article

View all access options for this article.

References

Pope

Aufderheide

Ruthazer

. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med 2000; 342: 1163–1170.

Manini

Gisondi

van d

. Adverse cardiac events in emergency department patients with chest pain six months after a negative inpatient evaluation for acute coronary syndrome. Acad Emerg Med 2002; 9: 896–902.

Thygesen

Alpert

Jaffe

. Third universal definition of myocardial infarction. Circulation 2012; 126: 2020–2035.

Heinecke

. Oxidative stress: New approaches to diagnosis and prognosis in atherosclerosis. Am J Cardiol 2003; 91: 12A–16A.

Stocker

Keaney

Jr . Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84: 1381–1478.

Cai

Harrison

. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ Res 2000; 87: 840–844.

Vita

Brennan

Gokce

. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 2004; 110: 1134–1139.

Hare

Stamler

. NO/redox disequilibrium in the failing heart and cardiovascular system. J Clin Invest 2005; 115: 509–517.

Chen

Keaney

. Reactive oxygen species-mediated signal transduction in the endothelium. Endothelium 2004; 11: 109–121.

10.

Hampton

Kettle

Winterbourn

. Inside the neutrophil phagosome: Oxidants, myeloperoxidase, and bacterial killing. Blood 1998; 92: 3007–3017.

11.

Daugherty

Dunn

Rateri

. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994; 94: 437–444.

12.

Hazen

Heinecke

. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest 1997; 99: 2075–2081.

13.

Upston

Niu

Brown

. Disease stage-dependent accumulation of lipid and protein oxidation products in human atherosclerosis. Am J Pathol 2002; 160: 701–710.

14.

Zheng

Nukuna

Brennan

. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004; 114: 529–541.

15.

Brennan

Penn

Van

. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003; 349: 1595–1604.

16.

Baldus

Heeschen

Meinertz

. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003; 108: 1440–1445.

17.

Baldus

Rudolph

Roiss

. Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation 2006; 113: 1871–1878.

18.

Mocatta

Pilbrow

Cameron

. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol 2007; 49: 1993–2000.

19.

Mockel

Danne

Muller

. Development of an optimized multimarker strategy for early risk assessment of patients with acute coronary syndromes. Clin Chim Acta 2008; 393: 103–109.

20.

Hamm

. [Guidelines: acute coronary syndrome (ACS). 1: ACS without persistent ST segment elevations]. Z Kardiol 2004; 93: 72–90.

21.

Hamm

. [Guidelines: Acute coronary syndrome (ACS). II: Acute coronary syndrome with ST-elevation]. Z Kardiol 2004; 93: 324–341.

22.

Muller

Mockel

. Logistic regression and CART in the analysis of multimarker studies. Clin Chim Acta 2008; 394: 1–6.

23.

Dokainish

Pillai

Murphy

. Prognostic implications of elevated troponin in patients with suspected acute coronary syndrome but no critical epicardial coronary disease: A TACTICS-TIMI-18 substudy. J Am Coll Cardiol 2005; 45: 19–24.

24.

Thygesen

Alpert

White

. Universal definition of myocardial infarction. Circulation 2007; 116: 2634–2653.

25.

James

Flodin

Johnston

. The antibody configurations of cardiac troponin I assays may determine their clinical performance. Clin Chem 2006; 52: 832–837.

26.

. Novel biomarkers of cardiovascular disease: Myeloperoxidase for acute and/or chronic heart failure? Clin Chem 2009; 55: 12–14.

27.

Shih

Datwyler

Hsu

. Effect of collection tube type and preanalytical handling on myeloperoxidase concentrations. Clin Chem 2008; 54: 1076–1079.

28.

Eggers

Dellborg

Johnston

. Myeloperoxidase is not useful for the early assessment of patients with chest pain. Clin Biochem 2010; 43: 240–245.

29.

McCann

Glover

Menown

. Prognostic value of a multimarker approach for patients presenting to hospital with acute chest pain. Am J Cardiol 2009; 103: 22–28.

30.

Apple

Pearce

Chung

. Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chem 2007; 53: 874–881.

31.

Morrow

Sabatine

Brennan

. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: Myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J 2008; 29: 1096–1102.

32.

Khan

Kelly

Quinn

. Myeloperoxidase aids prognostication together with N-terminal pro-B-type natriuretic peptide in high-risk patients with acute ST elevation myocardial infarction. Heart 2007; 93: 826–831.